
Jeplus.in
Purchase All Medicines.Get 10% Offer

PharmaShots
Shots: Immutep has reported new data from the investigator-initiated P-II (EFTISARC-NEO) study of eftilagimod alfa (efti) + Keytruda (pembrolizumab) & radiotherapy as neoadjuvant treatment in patients with high-risk, resectable soft tissue sarcoma at CTOS 2026 (Poster P 448); of 40 enrolled pts, 38 underwent surgery & were evaluated for survival The study showed a 12mos… The post Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 appeared first on PharmaShots.

PharmaShots
Shots: Ref: Globe Newswire  |  Image: Zealand Pharma  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight appeared first on PharmaShots.

Express Pharma
Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma.

PharmaShots
Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.

PharmaShots
Shots: Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy… The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.
Sponsored content

Purchase All Medicines.Get 10% Offer
News
PharmaShots
Nov 19, 2026, 6:09 AM
Shots: Immutep has reported new data from the investigator-initiated P-II (EFTISARC-NEO) study of eftilagimod alfa (efti) + Keytruda (pembrolizumab) & radiotherapy as neoadjuvant treatment in patients with high-risk, resectable soft tissue sarcoma at CTOS 2026 (Poster P 448); of 40 enrolled pts, 38 underwent surgery & were evaluated for survival The study showed a 12mos… The post Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 appeared first on PharmaShots.
PharmaShots
Nov 19, 2026, 6:06 AM
Shots: Ref: Globe Newswire  |  Image: Zealand Pharma  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight appeared first on PharmaShots.
Express Pharma
Nov 19, 2026, 4:35 AM
Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma.
ET Pharma
Nov 19, 2026, 2:18 AM
The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities.
ET Pharma
Nov 19, 2026, 2:14 AM
MNC body, OPPI, has submitted formal representations to the CDSCO, seeking a US FDA-style, time-bound review of new drug applications. The lobby may revise its key demand of granting regulatory data production from 10 years to six years, in line with the protection period recently introduced by China.
ET Pharma
Nov 19, 2026, 12:24 AM
Mazumdar-Shaw said early-stage, research-driven and pre-revenue biotech companies should be allowed to access public markets. Without such avenues, they risk being stranded without the capital needed to scale their research and businesses.
News
Google News
Nov 19, 2026, 5:40 AM
Sentiment Among Professionals and Executives in the Chemical and Pharmaceutical Industries Remains Stable  chemeurope.com
Google News
Nov 19, 2026, 4:16 AM
Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds  News-Medical
Google News
Nov 19, 2026, 4:05 AM
Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio  BusinessLine
Google News
Nov 19, 2026, 3:30 AM
Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative  Morningstar
Google News
Nov 19, 2026, 3:15 AM
Piramal Pharma to acquire remaining 26% stake in Yapan Bio  The Hindu
Google News
Nov 19, 2026, 3:08 AM
Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative  GlobeNewswire
Google News
Nov 19, 2026, 2:10 AM
Faster trials, less red tape. If Europe doesn’t act, patients could miss out on new treatments  EU Perspectives
Google News
Nov 19, 2026, 2:07 AM
Lotte chief calls biotech a key growth engine for group’s future  mkbn.mk.co.kr
Google News
Nov 19, 2026, 1:33 AM
VNVC and the American pharmaceutical company MSD announced a plan to cooperate in vaccine production at the VNVC factory, worth nearly 3 trillion VND.  Vietnam.vn
Sponsored placement

Purchase All Medicines.Get 10% Offer